Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting

Mer receptor tyrosine kinase is a therapeutic target in pre-B-cell acute lymphoblastic leukemia

(2013) R. M. A. Linger et al.   BLOOD

Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivo

(2013) A. Shieh et al.   BLOOD

DeregulatedMIR335that targetsMAPK1is implicated in poor outcome of paediatric acute lymphoblastic leukaemia

(2013) Junli Yan et al.   BRITISH JOURNAL OF HAEMATOLOGY

Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants

(2013) E. M. C. Driessen et al.   HAEMATOLOGICA

Notch1Gene Mutations Target KRAS G12D-expressing CD8+Cells and Contribute to Their Leukemogenic Transformation

(2013) Guangyao Kong et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Identification of Cryptotanshinone as an Inhibitor of Oncogenic Protein Tyrosine Phosphatase SHP2 (PTPN11)

(2013) Wei Liu et al.   JOURNAL OF MEDICINAL CHEMISTRY

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

(2013) Jonathan M. Ostrem et al.   NATURE

Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness

(2013) Qing Li et al.   NATURE

The genomic landscape of hypodiploid acute lymphoblastic leukemia

(2013) Linda Holmfeldt et al.   NATURE GENETICS

Activating Mutations in Protein Tyrosine Phosphatase Ptpn11 (Shp2) Enhance Reactive Oxygen Species Production That Contributes to Myeloproliferative Disorder

(2013) Dan Xu et al.   PLoS One

Targeting oncogenic Ras signaling in hematologic malignancies

(2012) A. F. Ward et al.   BLOOD

The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition

(2012) E J Haagensen et al.   BRITISH JOURNAL OF CANCER

Loss of CBL E3-ligase activity in B-lineage childhood acute lymphoblastic leukaemia

(2012) Simone Martinelli et al.   BRITISH JOURNAL OF HAEMATOLOGY

Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models

(2012) Ryan B. Corcoran et al.   CANCER CELL

Casitas B-cell lymphoma mutation in childhood T-cell acute lymphoblastic leukemia

(2012) Yuka Saito et al.   LEUKEMIA RESEARCH

The genetic basis of early T-cell precursor acute lymphoblastic leukaemia

(2012) Jinghui Zhang et al.   NATURE

Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner

(2011) J. Wang et al.   BLOOD

Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group

(2011) J. Zhang et al.   BLOOD

CBL mutations in infant acute lymphoblastic leukaemia

(2011) Norio Shiba et al.   BRITISH JOURNAL OF HAEMATOLOGY

Distinct requirements of hematopoietic stem cell activity and Nras G12D signaling in different cell types during leukemogenesis

(2011) Jinyong Wang et al.   CELL CYCLE

GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition

(2011) A. G. Gilmartin et al.   CLINICAL CANCER RESEARCH

Casitas B lymphoma mutations in childhood acute lymphoblastic leukemia

(2011) Lindsay Nicholson et al.   GENES CHROMOSOMES & CANCER

FLT3 mutation and expression did not adversely affect clinical outcome of childhood acute leukaemia-a study of 531 Southeast Asian children by the Ma-Spore study group

(2011) Shuangjie Leow et al.   HEMATOLOGICAL ONCOLOGY

Non–lineage/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatasePtpn11(Shp2) on malignant transformation of hematopoietic cells

(2011) Dan Xu et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy

(2011) L S Steelman et al.   LEUKEMIA

Activated K-Ras protein accelerates human MLL/AF4-induced leukemo-lymphomogenicity in a transgenic mouse model

(2011) H Tamai et al.   LEUKEMIA

CREBBP mutations in relapsed acute lymphoblastic leukaemia

(2011) Charles G. Mullighan et al.   NATURE

Regulating the regulator: post-translational modification of RAS

(2011) Ian M. Ahearn et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

(2011) Michelle C. Mendoza et al.   TRENDS IN BIOCHEMICAL SCIENCES

The prognostic impact of K-RAS mutations in adult acute myeloid leukemia patients treated with high-dose cytarabine

(2011) elhefni   OncoTargets and Therapy

Backtracking RAS mutations in high hyperdiploid childhood acute lymphoblastic leukemia

(2010) Joseph L. Wiemels et al.   BLOOD CELLS MOLECULES AND DISEASES

FLT3mutation incidence and timing of origin in a population case series of pediatric leukemia

(2010) Patrick Chang et al.   BMC CANCER

Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo

(2010) Kihyun Kim et al.   BRITISH JOURNAL OF HAEMATOLOGY

Blockade of Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase and Murine Double Minute Synergistically Induces Apoptosis in Acute Myeloid Leukemia via BH3-Only Proteins Puma and Bim

(2010) W. Zhang et al.   CANCER RESEARCH

Role of Ras/Raf/MEK/ERK signaling in physiological hematopoiesis and leukemia development

(2010) Eva Chung et al.   IMMUNOLOGIC RESEARCH

A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens

(2010) Jaafar Bennouna et al.   INVESTIGATIONAL NEW DRUGS

Relapsed childhood high hyperdiploid acute lymphoblastic leukemia: presence of preleukemic ancestral clones and the secondary nature of microdeletions and RTK-RAS mutations

(2010) J Davidsson et al.   LEUKEMIA

Genetic variegation of clonal architecture and propagating cells in leukaemia

(2010) Kristina Anderson et al.   NATURE

Initial testing (stage 1) of AZD6244 (ARRY-142886) by the pediatric preclinical testing program

(2010) E. Anders Kolb et al.   PEDIATRIC BLOOD & CANCER

Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents

(2010) M. Dail et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways

(2009) M. Rahmani et al.   BLOOD

Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study

(2009) Kirk R. Schultz et al.   JOURNAL OF CLINICAL ONCOLOGY

MEK inhibitors potentiate dexamethasone lethality in acute lymphoblastic leukemia cells through the pro-apoptotic molecule BIM

(2009) A A Rambal et al.   LEUKEMIA

PTPN11 mutations in childhood acute lymphoblastic leukemia occur as a secondary event associated with high hyperdiploidy

(2009) C G Molteni et al.   LEUKEMIA

Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras

(2009) Jennifer O. Lauchle et al.   NATURE

Oncogenic RAS Enables DNA Damage- and p53-Dependent Differentiation of Acute Myeloid Leukemia Cells in Response to Chemotherapy

(2009) Mona Meyer et al.   PLoS One

Oncogenic Kras Initiates Leukemia in Hematopoietic Stem Cells

(2009) Amit J Sabnis et al.   PLOS BIOLOGY

Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis

(2008) B. V. Balgobind et al.   BLOOD

K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to  -secretase inhibitors

(2008) T. Kindler et al.   BLOOD

Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation

(2008) J. Zhang et al.   BLOOD

Mutation of Genes Affecting the RAS Pathway Is Common in Childhood Acute Lymphoblastic Leukemia

(2008) M. Case et al.   CANCER RESEARCH

Tumour cell survival signalling by the ERK1/2 pathway

(2008) K Balmanno et al.   CELL DEATH AND DIFFERENTIATION

Patients With Acute Myeloid Leukemia andRASMutations Benefit Most From Postremission High-Dose Cytarabine: A Cancer and Leukemia Group B Study

(2008) Andreas Neubauer et al.   JOURNAL OF CLINICAL ONCOLOGY

BRAF mutations are very rare in B- and T-cell pediatric acute lymphoblastic leukemias

(2008) J Davidsson et al.   LEUKEMIA

Converting cell lines representing hematological malignancies from glucocorticoid-resistant to glucocorticoid-sensitive: Signaling pathway interactions

(2008) Anna S. Garza et al.   LEUKEMIA RESEARCH

Frequency of FLT3 mutations in childhood acute lymphoblastic leukemia

(2008) M. Braoudaki et al.   MEDICAL ONCOLOGY

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

(2008) Jeffrey A Engelman et al.   NATURE MEDICINE

Genomic Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic Leukemia

(2008) C. G. Mullighan et al.   SCIENCE

FLT3mutations in a 10 year consecutive series of 177 childhood acute leukemias and their impact on global gene expression patterns

(2007) Anna Andersson et al.   GENES CHROMOSOMES & CANCER